Long term F/U of CARES trial (febuxostat vs allopurinol) -remission incr from 37% (1,593/4,259) 1st Yr to 63% (322/510) @ yr 6. Over the 6 years, ~60 achieved remission at least once; more likely based on age, race, dz severity, comorbidities, & febuxo…
Post hoc Gout study of CARES trial (rx w/ ULT) showed remission @ 1yr increased from 37% to 63% at yr 6. In 6 yrs, 59% achieved remission 1+ times. Remission was signif assoc w/ age, race, Hi Dz severity, comorbidities, and febuxostat treatment acrjou…
Arthritis Care & Research doi.org/10.1002/acr....